• Antiviral therapy for patients with decompensated cirrhosis due to chronic hepatitis C: pros and cons
en To content Full text of article

Antiviral therapy for patients with decompensated cirrhosis due to chronic hepatitis C: pros and cons

International Journal Rehabilitation and Palliative Medicine. 2023. 1(8): 105-106; doi 10.15574/IJRPM.2023.8.105
Zaitsev I. A.
Bogomolets National Medical University, Kyiv, Ukraine

The effectiveness of hepatitis C treatment in patients with decompensated cirrhosis is about 90%. Further prognosis of the disease depends on liver cirrhosis. Since in Ukraine liver transplantation is not available to most patients, the question of the economic feasibility of treating such patients remains open.
According to the literature data, the survival rate in patients with cirrhosis and baseline MELD 10-15 is 96.0%, 93.6%, 89.7% within, respectively, 1, 2, 3 years after PPD treatment, and in patients with MELD ³16 – 85.9%, 82.4%, 71.7%, respectively. The overall mean short-term change in MELD was less than one point, and a clinically significant improvement of 3 MELD points occurred in only 24% of patients. According to other studies, an improvement within 2 points of MELD occurs in 40% of patients with decompensated cirrhosis with SVR. In the remaining 60%, the condition does not change or worsens, i.e. antiviral therapy acquires the features of a palliative therapy that improves the quality of life of patients, but does not affect the outcome of the disease.
The feasibility of prescribing antiviral therapy in patients with decompensated liver cirrhosis can be determined using the calculator, which assesses the likelihood of reaching CPT-A and the risk of death during the first year of follow-up.
No conflict of interests was declared by the authors.
Keywords: viral hepatitis, cirrhosis, direct acting antiviral drug, liver transplantation, mortality, survival, prognosis.

REFERENCES

1. Verna EC et al. (2020). DAA therapy and long-term hepatic function in advanced / decompensated cirrhosis: Real-world experience from HCV-TARGET cohort. J hepatology. 73: 540-548. https://doi.org/10.1016/j.jhep.2020.03.031; PMid:32243960